Travere Q1 2025 net product sales $75.9M, FILSPARI U.S. sales up 182% YoY; net loss narrows to $41.2M

Travere Therapeutics, Inc.

2025-Q1 EPS reported -$0.47 revenue$81,732,000

FILSPARI U.S. net product sales $55.9M in Q1 2025, up 182% YoY; 703 new patient start forms received.
Net loss of $41.2M ($0.47/share) vs $136.1M ($1.76) in Q1 2024; non-GAAP net loss $16.9M ($0.19).
sNDA for full approval of FILSPARI in FSGS submitted March 2025; FDA acceptance decision expected May 2025.
European Commission converted FILSPARI to standard MA for IgAN; expects $17.5M milestone from CSL Vifor in Q2 2025.
Cash, cash equivalents, and marketable securities $322.2M as of March 31, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.